Amgen "sell," target price reduced

31.07.07 - Lazard Capital Markets

NEW YORK, July 31 (newratings.com) - Analysts at Lazard Capital reiterate their "sell" rating on Amgen Inc (AMGN). The target price has been reduced from $44 to $41.